Spain's Grifols Acquires Stake in Shanghai RAAS, a Plasma Company, for $1.9 Billion
publication date: Mar 8, 2019
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidiary, Grifols Diagnostic Solutions, for the Shanghai RAAS stake. As part of the agreement, Shanghai RAAS will become exclusive distributor of Grifols' plasma-based and diagnostic products in China, including Grifol's nucleic acid test (NAT) systems used to screen plasma donors for HIV and HCV. More details....
Stock Symbols:(MCE: GRF, MCE: NSDQ: GRFS) (SHZ: 002252)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.